Latest Mirum Pharmaceuticals News & Updates

See the latest news and media coverage for Mirum Pharmaceuticals. We track all announcements, press releases, and industry mentions in real time, all in one place.

Mirum Pharmaceuticals

Rare disease biopharmaceutical company

mirumpharma.com

Headquarters: Foster City, United States
Founded year: 2018
Company type: Public company
Number of employees: 450–500

Last updated Today

Latest news about Mirum Pharmaceuticals

In short: Mirum Pharmaceuticals advanced its rare disease pipeline, securing FDA Priority Review for zilurgisertib and reporting positive clinical study data.

Company announcements

June 14 Mirum Pharmaceuticals

Mirum and Incyte announce positive Phase 2 results for zilurgisertib

FDA accepted NDA for zilurgisertib under Priority Review, with PDUFA date September 26, 2026.

June 4 Mirum Pharmaceuticals

Mirum and Incyte announce pivotal zilurgisertib results for ENDO 2026

Results from Cohort 1 of the PROGRESS study underpin the NDA, which has been granted Priority Review with a PDUFA date of September 26, 2026.

May 30 Mirum Pharmaceuticals

Mirum Pharmaceuticals announces new data from rare liver disease programs

Results from VISTAS, AZURE-1, and LIVMARLI studies presented at EASL Congress 2026 show positive efficacy and safety.

May 12 Mirum Pharmaceuticals

Mirum Pharmaceuticals prices $600 million convertible senior notes offering

The offering refinances a portion of its 2029 convertible notes.

Media coverage

June 14 Morningstar

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from...

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva - Cohort 1 results presented at...

June 4 Yahoo Finance

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

Mirum and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for ENDO 2026...

June 4 Yahoo Finance

Mirum Pharmaceuticals (MIRM) Reports Positive Phase 2b Data for Volixibat in PSC at EASL Congress

Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is one of the best high short interest stocks with highest upside potential. On May 30, Mirum Pharmaceuticals reported positive results...

May 30 GuruFocus

Mirum Pharmaceuticals (MIRM) Unveils Positive Data at EASL Congr

On May 31, 2026, Mirum Pharmaceuticals Inc (MIRM) revealed promising results from its programs targeting rare liver diseases during the EASL International Liver...

Never miss news about Mirum Pharmaceuticals

Track Mirum Pharmaceuticals and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.